No retraction, correction or concern found when last checked on Oct 23, 2026.
The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis
Lele Song, Jia Jia, Xiumei Peng and 2 more
Scientific Reports · 2017 · Meta-analysis · CC BY
doi:10.1038/s41598-017-03321-8
Abstract
The SEPT9 gene methylation assay is the first FDA-approved blood assay for colorectal cancer (CRC) screening. Fecal immunochemical test (FIT), FIT-DNA test and CEA assay are also in vitro diagnostic (IVD) tests used in CRC screening. This meta-analysis aims to review the SEPT9 assay performance and compare it with other IVD CRC screening tests. By searching the Ovid MEDLINE, EMBASE, CBMdisc and CJFD database, 25 out of 180 studies were identified to report the SEPT9 assay performance. 2613 CRC cases and 6030 controls were included, and sensitivity and specificity were used to evaluate its performance at various algorithms. 1/3 algorithm exhibited the best sensitivity while 2/3 and 1/1 algorithm exhibited the best balance between sensitivity and specificity. The performance of the blood SEPT9 assay is superior to that of the serum protein markers and the FIT test in symptomatic population, while appeared to be less potent than FIT and FIT-DNA tests in asymptomatic population. In conclusion, 1/3 algorithm is recommended for CRC screening, and 2/3 or 1/1 algorithms are suitable for early detection for diagnostic purpose. The SEPT9 assay exhibited better performance in symptomatic population than in asymptomatic population.
References 37
- 1.
National Cancer Institute. Survival rate for colorectal cancer by stage, Physician Data Query, Treatment, Health Professionals 1999 (1999).
Not in our library
- 2.
Lin JS, et al. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016;315:2576-94.
Not in our library10.1001/jama.2016.3332
- 3.
Lofton-Day C, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem. 2008;54:414-23.
Not in our library10.1373/clinchem.2007.095992
- 4.
- 5.
- 6.
- 7.
Church TR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317-25.
Not in our library10.1136/gutjnl-2012-304149
- 8.
- 9.
Potter NT, et al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin Chem. 2014;60:1183-91.
Not in our library10.1373/clinchem.2013.221044
- 10.
Wu D, et al. Detection of Colorectal Cancer Using a Simplified SEPT9 Gene Methylation Assay Is a Reliable Method for Opportunistic Screening. J Mol Diagn. 2016;18:535-45.
Not in our library10.1016/j.jmoldx.2016.02.005
- 11.
Song L, et al. Algorithm Optimization in Methylation Detection with Multiple RT-qPCR. PLoS One. 2016;11:e0163333.
Not in our library10.1371/journal.pone.0163333
- 12.
Ahlquist DA, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol. 2012;10:272-277.
Not in our library10.1016/j.cgh.2011.10.008
- 13.
- 14.
Weiss G, Rosch T. Potential of a new blood test for colorectal cancer screening—the Septin 9 gene biomarker. Eur Oncol. 2010;6:51-54.
Not in our library
- 15.
Liu Y, et al. Serum methylation levels of TAC1. SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: a pilot study. Biomarkers. 2013;18:399-405.
Not in our library10.3109/1354750x.2013.798745
- 16.
He Q, et al. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer. Cancer Genet Cytogenet. 2010;202:1-10.
Not in our library10.1016/j.cancergencyto.2010.05.018
- 17.
Wang Z, et al. The application of MS-HRM detection of free methylated SEPT9 in early diagnosis of colorectal cancer. Guangdong Medical Journal. 2012;33:1732-1734.
Not in our library
- 18.
Li SJ, et al. The study of peripheral methylation SEPT9 in screening colorectal cancer. Chin J Gen Surg. 2015;124:1756-1760.
Not in our library
- 19.
He Q, et al. Detection of ALX4 and SEPT9 methylation in human colorectal cancer by Multiplex MethyLight assay. J Sun Yat-Sen Univ (Med Sci). 2015;36:657-662.
Not in our library
- 20.
Tóth K, et al. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. PLoS One. 2014;9:e115415.
Not in our library10.1371/journal.pone.0115415
- 21.
Kang Q, et al. Significance of Septin9 gene methylation detection of plasma circulation DNA in colorectal cancer screening. Zhonghua Yi Xue Za Zhi. 2014;94:3839-41.
Not in our library
- 22.
He N, et al. Clinical significance of detecting serum methylated Sept9 gene in diagnosis of colorectal cancer. Chin J Dig. 2014;34:726-731.
Not in our library
- 23.
Jin P, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol. 2015;30:830-3.
Not in our library10.1111/jgh.12855
- 24.
Yu D, Zhang XH, Lu XX. Study on diagnostic value of SEPT9 gene methylation in serum for colorectal cancer. Chin J Clin Lab Sci. 2015;33:687-689.
Not in our library
- 25.
Ding QQ, et al. Study of methylation SEPT9 for colorectal cancer screening in aged population. Chin J Geriatr. 2015;34:1348-1350.
Not in our library
- 26.
deVos T, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009;5:1337-46.
Not in our library10.1373/clinchem.2008.115808
- 27.
- 28.
- 29.
Ørntoft MB, et al. Danish Study Group on Early Detection of Colorectal Cancer. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study. BMC Cancer. 2015;15:819.
Not in our library10.1186/s12885-015-1832-6
- 30.
- 31.
- 32.
Liu Z, et al. A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer. PLoS One. 2014;9:e103910.
Not in our library10.1371/journal.pone.0103910
- 33.
Lee JK, et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160:171.
Not in our library10.7326/m13-1484
- 34.
Imperiale TF, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287-97.
Not in our library10.1056/nejmoa1311194
- 35.
- 36.
Mayo E, Kinzler M, Zhang L. Considerations for Conducting Meta-analysis in Diagnostic Pathology. Arch Pathol Lab Med. 2015;139:1331.
Not in our library10.5858/arpa.2015-0064-le
- 37.
Marchevsky AM, Wick MR. Evidence-based pathology: systematic literature reviews as the basis for guidelines and best practices. Arch Pathol Lab Med. 2015;139:394-399.
Not in our library10.5858/arpa.2014-0106-ra
Cited by papers we hold 7
- Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia · 2024No notice
- Novel Diagnostic Biomarkers in Colorectal Cancer · 2022No notice
- Targeted Bisulfite Sequencing Reveals DNA Methylation Changes in Zinc Finger Family Genes Associated With KRAS Mutated Colorectal Cancer · 2021Not checked
- A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis · 2021No notice
- DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types · 2020No notice
- Next-generation sequencing in liquid biopsy: cancer screening and early detection · 2019No notice
- Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management · 2018No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.